Kiniksa Pharmaceuticals International, plc (KNSA) insider trading.
In Q3 2026, insiders at Kiniksa Pharmaceuticals International, plc reported 36 non-derivative transactions on 11 Forms 3, 4 and 5: 0 open-market purchases and 2 sales worth $668K.
- Transactions
- 36
- Purchases (P)
- 0
- Sales (S)
- 2
- Net shares, P minus S
- -8,273
- Insiders
- 8
- Last filed
- 2026-09-03
Insiders
| Insider | Relationship | Transactions | Buys | Sales |
|---|---|---|---|---|
| Patel Sanj K | Director, Officer · CHAIRMAN & CEO | 10 | 0 | 0 |
| Megna Michael R | Officer · CHIEF ACCOUNTING OFFICER | 7 | 0 | 1 |
| Paolini John F. | Officer · CHIEF MEDICAL OFFICER | 5 | 0 | 0 |
| Ragosa Mark | Officer · CHIEF FINANCIAL OFFICER | 5 | 0 | 0 |
| Moat Ross | Officer · CHIEF OPERATING OFFICER | 5 | 0 | 0 |
| Cole G Bradley | Director | 2 | 0 | 1 |
| Quart Barry D | Director | 1 | 0 | 0 |
| Levy Richard S | Director | 1 | 0 | 0 |
Transactions
| Date | Insider | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-03 | Megna Michael R | S (D) | 4,600 | $80.3 | 29,062 | Form 4 |
| 2026-09-01 | Megna Michael R | F (D) | 5,531 | $79.28 | 33,662 | Form 4 |
| 2026-09-01 | Megna Michael R | M (A) | 2,362 | — | 36,549 | Form 4 |
| 2026-09-01 | Megna Michael R | M (A) | 2,558 | — | 34,187 | Form 4 |
| 2026-09-01 | Megna Michael R | M (A) | 3,932 | — | 31,629 | Form 4 |
| 2026-09-01 | Megna Michael R | M (A) | 2,644 | — | 39,193 | Form 4 |
| 2026-09-01 | Patel Sanj K | M (A) | 6,237 | — | 98,883 | Form 4 |
| 2026-09-01 | Patel Sanj K | M (A) | 8,609 | — | 107,492 | Form 4 |
| 2026-09-01 | Patel Sanj K | F (D) | 15,144 | $79.28 | 92,348 | Form 4 |
| 2026-09-01 | Patel Sanj K | M (A) | 6,481 | — | 92,646 | Form 4 |
| 2026-09-01 | Patel Sanj K | M (A) | 9,991 | — | 86,165 | Form 4 |
| 2026-09-01 | Patel Sanj K | M (A) | 6,237 | — | 98,883 | Form 4 |
| 2026-09-01 | Patel Sanj K | F (D) | 15,144 | $79.28 | 92,348 | Form 4 |
| 2026-09-01 | Patel Sanj K | M (A) | 6,481 | — | 92,646 | Form 4 |
| 2026-09-01 | Patel Sanj K | M (A) | 9,991 | — | 86,165 | Form 4 |
| 2026-09-01 | Patel Sanj K | M (A) | 8,609 | — | 107,492 | Form 4 |
| 2026-09-01 | Paolini John F. | M (A) | 1,624 | — | 69,744 | Form 4 |
| 2026-09-01 | Paolini John F. | M (A) | 2,457 | — | 73,951 | Form 4 |
| 2026-09-01 | Paolini John F. | M (A) | 1,750 | — | 71,494 | Form 4 |
| 2026-09-01 | Paolini John F. | F (D) | 4,029 | $79.28 | 69,922 | Form 4 |
| 2026-09-01 | Paolini John F. | M (A) | 2,497 | — | 68,120 | Form 4 |
| 2026-09-01 | Ragosa Mark | M (A) | 2,694 | — | 18,848 | Form 4 |
| 2026-09-01 | Ragosa Mark | M (A) | 1,750 | — | 20,598 | Form 4 |
| 2026-09-01 | Ragosa Mark | F (D) | 4,404 | $79.28 | 20,854 | Form 4 |
| 2026-09-01 | Ragosa Mark | M (A) | 3,069 | — | 25,258 | Form 4 |
| 2026-09-01 | Ragosa Mark | M (A) | 1,591 | — | 22,189 | Form 4 |
| 2026-09-01 | Moat Ross | M (A) | 1,611 | — | 16,117 | Form 4 |
| 2026-09-01 | Moat Ross | F (D) | 4,007 | $79.28 | 16,307 | Form 4 |
| 2026-09-01 | Moat Ross | M (A) | 2,457 | — | 20,314 | Form 4 |
| 2026-09-01 | Moat Ross | M (A) | 1,740 | — | 17,857 | Form 4 |
| 2026-09-01 | Moat Ross | M (A) | 2,477 | — | 14,506 | Form 4 |
| 2026-08-19 | Quart Barry D | G (D) | 2,600 | $0 | 12,745 | Form 4 |
| 2026-08-01 | Levy Richard S | M (A) | 403 | — | 22,359 | Form 4 |
| 2026-07-29 | Cole G Bradley | G (D) | 4,500 | $0 | 7,172 | Form 4 |
| 2026-07-29 | Cole G Bradley | S (D) | 3,673 | $81.43 | 11,672 | Form 4 |
| 2026-07-15 | Megna Michael R | A (A) | 279 | $33.5 | 27,697 | Form 4 |
Transaction codes in this quarter
Get KNSA insider transactions through the API
curl "https://sec-api.dev/api/v1/insider-transactions?period=2026q3&cik=1730430&limit=100" \
-H "Authorization: Bearer $SEC_API_KEY"Insider trading API guide · KNSA company page · Kiniksa Pharmaceuticals International, plc on SEC.gov
Questions
Are insiders buying or selling Kiniksa Pharmaceuticals International, plc (KNSA)?
In Q3 2026, insiders at Kiniksa Pharmaceuticals International, plc reported 36 non-derivative transactions on 11 Forms 3, 4 and 5: 0 open-market purchases and 2 sales worth $668K. Grants, tax withholding and option exercises are counted as transactions but are not purchases or sales.
Where do these Kiniksa Pharmaceuticals International, plc insider trades come from?
From the SEC Insider Transactions Data Sets for Q3 2026, which republish the Forms 3, 4 and 5 filed on EDGAR. Each row links to its filing on SEC.gov.
Plain-text version for agents and LLMs: /insider-trading/knsa.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.